Investors may find better financial performance in REGENXBIO Inc. (RGNX)

REGENXBIO Inc. [RGNX] stock is trading at $22.56, up 0.58%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RGNX shares have gain 6.42% over the last week, with a monthly amount glided 1.12%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

On 22, November 2022, REGENXBIO to Participate in Upcoming Investor Conferences. In a post published today on Yahoo Finance, REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:.

From an analyst’s perspective:

REGENXBIO Inc. [NASDAQ: RGNX] stock has seen the most recent analyst activity on June 23, 2022, when Berenberg initiated its Buy rating and assigned the stock a price target of $61. Previously, Wedbush started tracking the stock with Neutral rating on December 15, 2021, and set its price target to $29. Raymond James upgraded its rating to a Strong Buy but stick to its price target of $60 on January 06, 2021. UBS initiated its recommendation with a Buy and recommended $57 as its price target on December 16, 2020.

REGENXBIO Inc. [RGNX] stock has fluctuated between $18.69 and $36.35 over the past year. Currently, Wall Street analysts expect the stock to reach $44.70 within the next 12 months. REGENXBIO Inc. [NASDAQ: RGNX] shares were valued at $22.56 at the most recent close of the market. An investor can expect a potential return of 98.14% based on the average RGNX price forecast.

Analyzing the RGNX fundamentals

REGENXBIO Inc. [NASDAQ:RGNX] reported sales of 26.51 billion for the most recent quarter, which represents a drop of -14.00%. Gross Margin for this corporation currently stands at +86.95% with Operating Margin at +34.01%, Pretax Margin comes in at +30.03%, and Net Margin reading is +27.18%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.18 points at the first support level, and at 21.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.85, and for the 2nd resistance point, it is at 23.14.

REGENXBIO Inc. [RGNX] reported earnings per share of -$1.58 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.53/share, meaning a difference of -$0.05 and a surprise factor of -3.30%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$1.79 per share as compared to estimates of -$1.32 per share, a difference of -$0.47 representing a surprise of -35.60%.

Ratios To Look Out For

For context, REGENXBIO Inc.’s Current Ratio is 3.50. Further, the Quick Ratio stands at 3.98, while the Cash Ratio is 3.51. Considering the valuation of this stock, the price to sales ratio is 3.05, the price to book ratio is 1.83 and the P/E (TTM) ratio is 24.34.

Transactions by insiders

Insider trading, which has resulted in 0 insider purchases of 0 shares and 1 insider sales of 2,400 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Vasista Vittal, Chief Financial Officer, that happened on Aug 30 when 2400.0 shares were sold. Chief Financial Officer, Vasista Vittal completed a deal on Aug 05 to sell 17280.0 shares. Meanwhile, Chief Financial Officer Vasista Vittal sold 400.0 shares on Aug 04.